Related Experiment Video
Updated: Sep 2, 2025
02:34
Author Spotlight: Efficacy of Auricular Pressure Bean Therapy in Reducing Wheezing Symptoms
Published on: May 10, 2024
1.1K
Intermittent Tiotropium Bromide for Episodic Wheezing: A Randomized Trial.
Anne Kotaniemi-Syrjänen1, Timo Klemola2, Petri Koponen3
1HUS Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Pediatrics
|August 9, 2022
Summary
Intermittent tiotropium bromide effectively increased episode-free days in young children with episodic wheezing. This treatment offers a promising alternative for managing recurrent respiratory symptoms in early childhood.
Area of Science:
- Pediatric Pulmonology
- Respiratory Medicine
- Clinical Trials
Background:
- Episodic wheezing in children presents limited treatment and prevention options.
- Early childhood respiratory conditions require effective management strategies.
Purpose of the Study:
- To evaluate the efficacy of intermittent tiotropium bromide for treating episodic wheezing in young children.
- To compare tiotropium bromide with fluticasone propionate and albuterol sulfate for managing wheezing episodes.
Main Methods:
- A 48-week randomized, open-label, controlled trial involving children aged 6-35 months with recurrent wheezing.
- Three treatment arms: intermittent tiotropium bromide, intermittent fluticasone propionate, or as-needed albuterol sulfate, all with rescue albuterol.
- Primary outcome measured by the proportion of episode-free days.
Main Results:
- Intermittent tiotropium bromide significantly increased episode-free days compared to fluticasone propionate (97% vs 87%) and albuterol alone (97% vs 88%).
- Results remained consistent after adjusting for allergic sensitization and baseline symptom frequency.
- No intervention-related adverse events were reported.
Conclusions:
- Intermittent tiotropium bromide demonstrates potential as an effective treatment for childhood episodic wheezing.
- Further research is warranted to confirm the safety and efficacy profile of this therapeutic approach.
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:23Inhaled Medications
370
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
370
01:26COPD: Management Using Bronchodilators and Corticosteroids
284
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
284
01:19Antiasthma Drugs: Leukotriene Modifiers
429
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
429
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
351
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
351
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
414
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
414